BusinessMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and DevelopmentBy Nasdaq OMXSep 11, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderBy Nasdaq OMXSep 5, 2017, 12:00 PM UTC
BusinessMinerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With JanssenBy Nasdaq OMXAug 25, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences Reports Second Quarter 2017 Financial Results and Business UpdatesBy Nasdaq OMXAug 3, 2017, 11:30 AM UTC
BusinessAmerican Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in SchizophreniaBy Nasdaq OMXJul 31, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017By Nasdaq OMXJul 27, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Departure of DirectorsBy Nasdaq OMXJul 24, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesBy Nasdaq OMXJul 5, 2017, 8:05 PM UTC
